NIH Goes Virtual for Hidden Medical Grant Reviews
Published Date: 4/11/2025
Notice
Summary
The National Institute of General Medical Sciences is holding a private virtual meeting from April 25-28, 2025, to review special grant applications for small businesses. This closed meeting protects sensitive info like trade secrets and personal details. It affects researchers and companies seeking funding, with no direct cost changes but important decisions on who gets grants.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Closed SBIR Review Meeting Scheduled
If you are a researcher or small business applying for SBIR grants, the National Institute of General Medical Sciences will hold a closed virtual review meeting April 25-28, 2025, from 9:00 a.m. to 6:00 p.m. each day to review and evaluate grant applications. The meeting is listed as virtual but the NIH address is Natcher Building, 45 Center Drive, Bethesda, Maryland 20892.
Confidentiality for Trade Secrets and Personal Data
If you submit an SBIR grant application, the review meeting will be closed to protect confidential trade secrets, commercial property (including patentable material), and personal information. The closure is under 5 U.S.C. 552b(c)(4) and 552b(c)(6), which the notice cites as the reason for keeping the April 25-28, 2025 meeting private.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2025-06174, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on May 13-14, 2025, to review grant applications for small businesses working on anti-infective and immune disease treatments. This private meeting protects sensitive info like trade secrets and personal details. Small businesses aiming for funding should keep an eye on this important review process happening soon.
Next: 2025-06176, Center for Scientific Review; Cancellation of Meeting
The Center for Scientific Review has canceled its special meeting scheduled for May 1-2, 2025, in Bethesda, MD. This affects researchers and participants who planned to attend, but no costs or deadlines are changing. Everyone can relax and save their time since the event won’t happen as planned.